A 25-year study of the clinical and histologic outcomes of hepatitis C virus infection and its modes of transmission in a cohort of initially asymptomatic blood donors

Journal of Infectious Diseases

Volumn 206, Issue 5, 2012, Pages 654-661

  Allison, Robert D ^a   Conry Cantilena, Cathy ^a   Koziol, Deloris ^b   Schechterly, Cathy ^a   Ness, Paul ^e   Gibble, Joan ^f   Kleiner, David E ^c   Ghany, Marc G ^d   Alter, Harvey J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Biostatistics and Clinical Epidemiology Service   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e DEPARTMENT OF PATHOLOGY   (United States)

^f American Red Cross ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; COCAINE; INTERFERON; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CLASSIFICATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG USE; FEMALE; FOLLOW UP; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; SCORING SYSTEM;

ADULT; ANTIBODIES, VIRAL; BIOPSY; BLOOD DONORS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOBLOTTING; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, VIRAL;

EID: 84864955523     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis410     Document Type: Article

References (22)

1. Alter MJ. Hepatitis C virus infection in the United States. J Hepatol 1999; 31:88-91. (Pubitemid 30002698)
2. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127:27-34.
3. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334:1691-6. (Pubitemid 26193620)
4. Tobler LH, Lee SR, Stramer SL, et al. Performance of second and third-generation RIBAs for confirmation of third-generation HCV EIA-reactive blood donations. Retrovirus Epidemiology Donor Study. Transfusion 2000; 40:917-23.
5. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-9.
6. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19:1513-20. (Pubitemid 24166476)
7. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431-5. (Pubitemid 12218164)
8. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332:1463-6.
9. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12:671-5. (Pubitemid 20349249)
10. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28:1687-95. (Pubitemid 28549142)
11. Karmochkine M, Carrat F, Dos Santos O, Cacoub P, Raguin G. A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. J Viral Hepat 2006; 13:775-82. (Pubitemid 44583504)
12. Tortu S, McMahon JM, Pouget ER, Hamid R. Sharing of noninjection drug-use implements as a risk factor for hepatitis C. Subst Use Misuse 2004; 39:211-24. (Pubitemid 38365497)
13. McMahon JM, Simm M, Milano D, Clatts M. Detection of hepatitis C virus in the nasal secretions of an intranasal drug-user. Ann Clin Microbiol Antimicrob 2004; 3:6.
14. Wiese M, Gruengreiff K, Guethoff W, Lafrenz M, Oesen U, Porst H. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany-a 25-year multicenter study. J Hepatol 2005; 43:590-8. (Pubitemid 41253225)
15. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340:1228-33. (Pubitemid 29181642)
16. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001; 33:455-63. (Pubitemid 32119036)
17. Vogt M, Lang T, Froesner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341:866-70. (Pubitemid 29427048)
18. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349:825-32. (Pubitemid 27129209)
19. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355:2444-51. (Pubitemid 44903748)
20. Poordad F, McCone J Jr, Bacon BR, et al. Bocepravir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-206.
21. Zeuzem S, Anderone P, Pol S, et al. Telapravir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-28.
22. Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000; 132:105-11. (Pubitemid 30044176)